McAfee John L, Alban Tyler J, Makarov Vladimir, Rupani Amit, Parthasarathy Prerana B, Tu Zheng, Ronen Shira, Billings Steven D, Diaz C Marcela, Chan Timothy A, Ko Jennifer S
Department of Pathology, Cleveland Clinic Pathology and Laboratory Medicine Institute, Cleveland, Ohio.
Center for Immunotherapy and Precision Immuno-Oncology and Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.
Lab Invest. 2025 Feb;105(2):102183. doi: 10.1016/j.labinv.2024.102183. Epub 2024 Nov 10.
Superficial malignant peripheral nerve sheath tumors (SF-MPNSTs) are rare cancers and can be difficult to distinguish from spindle cell (SCM) or desmoplastic (DM) melanomas. Their biology is poorly understood. We performed whole-exome sequencing and RNA sequencing (RNA-seq) on SF-MPNST (n = 8) and compared them with cases of SCM (n = 7), DM (n = 8), and deep MPNST (D-MPNST, n = 8). Immunohistochemical staining for H3K27me3 and PRAME was also performed. SF-MPNST demonstrated intermediate features between D-MPNST and melanoma. Patients were younger than those with melanoma and older than those with D-MPNST; the outcome was worse and better, respectively. SF-MPNST tumor mutational burden (TMB) was higher than D-MPNST and lower than melanoma; differences were significant only between SF-MPNST and SCM (P = .0454) and between D-MPNST and SCM (P = .001, Dunn's Kruskal-Wallis post hoc test). Despite having an overlapping mutational profile in some common cancer-associated genes, the COSMIC mutational signatures clustered DM and SCM together with UV light exposure signatures (SBS7a, 7b), and SF- and D-MPNST together with defective DNA base excision repair (SBS30, 36). RNA-seq revealed differentially expressed genes between SF-MPNST and SCM (1670 genes), DM (831 genes), and D-MPNST (614 genes), some of which hold promise for development as immunohistochemical markers (SOX8 and PLCH1) or aids (MLPH, CALB2, SOX11, and TBX4). H3K27me3 immunoreactivity was diffusely lost in most D-MPNSTs (7/8, 88%) but showed variable and patchy loss in SF-MPNSTs (2/8, 25%). PRAME was entirely negative in the majority (0+ in 20/31, 65%), including 11/15 melanomas, and showed no significant difference between groups (P = .105, Kruskal-Wallis test). Expression of immune cell transcripts was upregulated in melanomas relative to MPNSTs. Next-generation sequencing revealed multiple differential features between SF- MPNST, D-MPNST, SCM, and DM, including tumor mutation burden, mutational signatures, and differentially expressed genes. These findings help advance our understanding of disease pathogenesis and improve diagnostic modalities.
浅表性恶性外周神经鞘瘤(SF-MPNSTs)是罕见的癌症,可能难以与梭形细胞(SCM)或促纤维增生性(DM)黑色素瘤区分开来。人们对其生物学特性了解甚少。我们对SF-MPNST(n = 8)进行了全外显子组测序和RNA测序(RNA-seq),并将其与SCM(n = 7)、DM(n = 8)和深部MPNST(D-MPNST,n = 8)病例进行比较。还进行了H3K27me3和PRAME的免疫组织化学染色。SF-MPNST表现出介于D-MPNST和黑色素瘤之间的中间特征。患者比黑色素瘤患者年轻,比D-MPNST患者年长;结果分别更差和更好。SF-MPNST的肿瘤突变负荷(TMB)高于D-MPNST且低于黑色素瘤;差异仅在SF-MPNST和SCM之间(P = 0.0454)以及D-MPNST和SCM之间具有统计学意义(P = 0.001,Dunn氏Kruskal-Wallis事后检验)。尽管在一些常见的癌症相关基因中具有重叠的突变谱,但COSMIC突变特征将DM和SCM与紫外线暴露特征(SBS7a、7b)归为一类,而将SF-和D-MPNST与缺陷性DNA碱基切除修复(SBS30、36)归为一类。RNA-seq揭示了SF-MPNST与SCM(1670个基因)、DM(831个基因)和D-MPNST(614个基因)之间的差异表达基因,其中一些有望开发为免疫组织化学标志物(SOX8和PLCH1)或辅助工具(MLPH、CALB2、SOX11和TBX4)。H3K27me3免疫反应性在大多数D-MPNST中(7/8,88%)弥漫性丧失,但在SF-MPNST中表现为可变的斑片状丧失(2/8,25%)。PRAME在大多数病例中(20/31,65%为0+)完全阴性,包括11/15的黑色素瘤,且各组之间无显著差异(P = 0.105,Kruskal-Wallis检验)。相对于MPNSTs,黑色素瘤中免疫细胞转录本的表达上调。二代测序揭示了SF-MPNST、D-MPNST、SCM和DM之间的多个差异特征,包括肿瘤突变负荷、突变特征和差异表达基因。这些发现有助于加深我们对疾病发病机制的理解并改善诊断方式。